ZEPZELCA®(Lurbinectedin) has been approved in Hong Kong and Macao for the treatment of relapsed small cell lung cancer
2023
Luye Life Sciences attended SCO Conference on Traditional Medicine Industry
2023
Toronto Private Hospital team was acknowledged as finalists in the category of Excellence in Large Business at the iconic Business Hunter Awards (2023).
2023
Robina Private Hospital Won 2023 Awards for Excellence
2023
WPU signed an MoU with AstraZeneca Brazil and Brazilian Herbarium, to bring Xuezhikang to the Brazilian market
2023
Luye Life Sciences Launched Innovative Vaccine and Biotechnology Center Project in Uzbekistan
2023
Luye Pharma won the "2023 Most Branded Listed Company" award.
2023
The first Canberra-based mental health facility - Deakin Private Hospital was opened
2023
Luye Pharma and Boan Biotech won the 2022 Yantai Biopharmaceutical Industry High Quality Development and Innovation Award
2023
Luye Diagnostics（China）released China’s first non-invasive diagnostic kits for H. pylori and its DRMs
2023
Study tour to Australia on meatal health led by Mindfront Academy was concluded successfully, romoting academic exchange
2023
The world’s only Goserelin Microspheres for Injection (Baituowei) received marketing approval in China for the treatment of prostate cancer and breast cancer
2023
Rykindo® (risperidone) for extended-release injectable suspension received marketing approval in the U.S.，making it the first FDA approved new drug in the CNS therapeutic field developed from China
2022
Boan Biotech was listed on the main board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company
2022
Boyoubei® received marketing approval in China for the treatment of osteoporosis. It is the first denosumab injection developed locally in China.
2022
Ruoxinlin®(Toludesvenlafaxine Hydrochloride Extended-release Tablets), China’s first class 1 innovative chemical drug for the treatment of major depressive disorder, received marketing approval in China
2022
In February 2022, Mindfront opened a high-ened hospital in Xi’an to serve more patients suffering from mental health problems
2021
3 new Mindfront institutions were opened in Shanghai, Xi'an and Shenzhen
2021
Rivastigmine Multi-Day Transdermal Patch received marketing approval in several European countries, optimizing the treatment regimen for Alzheimer’s with an upgraded formulation
2021
Bevacizumab Injection received marketing authorization in China, becoming the 1st biologic developed by Boan Biotech to enter the market
2021
Rykindo® Approved in China. It's Luye's independently developed Risperidone Microspheres for Injection for the treatment of acute and chronic schizophrenia.
2020
The once-daily Rivastigmine Transdermal Patch received market approval in China, to help improve safe treatment for patients with Alzheimer's disease
2020
Acquired Boan Biotech, accelerating development in the field of biopharmaceuticals
2019
Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from the new drug
2019
Luye Medical Group establishes mental health division in China.
2019
Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets
2019
The Group creates a new brand system,
marking a💜 new era in building an international life sciences group
2018
Luye Pharma acquired the business of Seroquel
in 51 Countries and Regions from AstraZeneca
2017
Luye Group officially changed its name to
"Luye Life Sciences Group"
2017
Boston R&D Center was put into operation,
laying a solid technical foundation through collaboration
on new platforms and projects,
to help ens🍌ure the sustainable pipeline development.
2016
Luye Pharma acquired Europe's leading
transdermal drug delivery Business.
2016
Luye Medical acquired Healthe Care,
Australia's third largest private hospital group.
The international development has t🌄aken a solid step.
2015
Luye Pharma's self-developed microsphere product
LY03004 completed all rꦆegistered clinical research in the U.S.
2014
Several innovative preparations and new drugs were
registered in the U.S. for clinical research.
2013
The solid preparation production line of Luye Pharma passed
the EU GMP inspection.
2011
Luye Pharma acquired Sichuan Baoguang Pharmaceutical,
to𒁏 strengthen the endocrine and metabolic system product l𒉰ine.
2007
Luye Pharma acquired Nanjing Kanghai,
Nanjing Sike and Beijing Peking University WBL,
strengthening the oncology and ꩲcardiovascular product line.
2004
Luye Pharma first landed in the international
capital market, listed in Singapore.
2000
Established the "Golden Leaf medal” system to recognize
the Luyers who work and grew up with the co๊mpany.
1999
The Luye Pharma R&D Center was established.
1998
Luye Pharma Intellectual Property Department and
the International Cooperation Depar🃏tment were established.
1997
The revenue of Luye Pharma exceeded RMB 100 million.
TOP